2. Search Result
Search Result
Results for "

CTLs

" in MedChemExpress (MCE) Product Catalog:

56

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

44

Peptides

4

Inhibitory Antibodies

3

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Area
  • HY-P4193
    AH1

    		Peptides Inflammation/Immunology
    AH1 is an immunodominant antigen derived from the gp70 product of an endogenous MuLV. AH1 behaves as the CTL-immunodominant epitope of CT26 colon carcinoma .
  • HY-P2527
    Tyrosinase-related Protein 2 (TRP-2) (181-188)

    		Tyrosinase Inflammation/Immunology
    Tyrosinase-related Protein 2 (TRP-2) (181-188) is a tyrosinase-related protein 2 (TRP-2)-derived peptide, corresponding to residues 180-188. Tyrosinase-related Protein 2 (TRP-2) (181-188) is the major reactive epitope within TRP-2 recognized by anti-B16 CTLs. Tyrosinase-related Protein 2 (TRP-2) (181-188) is a peptide conforming to the MHC class I H2-Kb binding motif .
  • HY-P10496A
    MAGE-A1-derived peptide acetate

    		Peptides Cancer
    MAGE-A1-derived peptide acetate is a short peptide sequence derived from MAGE-A1 protein. As a tumor-specific antigen, MAGE-A1-derived peptide acetate can be recognized and activated by cytotoxic T lymphocytes (CTLs), thereby generating an immune response to tumor cells expressing MAGE-A1. This immune response can lead to the lysis and death of tumor cells. MAGE-A1-derived peptide acetate can be used in the study of tumor immunity .
  • HY-P2455
    LLO (91-99)

    Listeriolysin O (91-99)

    		 Bacterial Infection Inflammation/Immunology
    LLO (91-99) (Listeriolysin O (91-99)) is an exotoxin and class I MHC-restricted T-cell epitope of listeriolysin (LLO). LLO (91-99) is processed by antigen-presenting cells, binds to MHC class I molecules and is presented to the cell surface. LLO (91-99) induces CTL responses and effectively eliminates Listeria from infected cells. LLO (91-99) can be used in the research of Listeria infections (e.g., listeriosis) .
  • HY-P4032
    HCV Peptide (35-44)

    		HCV Inflammation/Immunology
    HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .
  • HY-P3644
    EEKLIVVAF

    		Peptides Cancer
    EEKLIVVAF is a pepitide, can be recognized on HLA-B44 by the anti-melanoma cytolytic T-cell (CTL) clone LB33- CTL-159/5 .
  • HY-P3070
    H2-D b restricted epitopes VSV Nucleoprotein (52-59)

    		MHC Infection Others
    H2-D b restricted epitopes VSV Nucleoprotein (52-59) is a 9-mer peptide derived from the nucleoprotein of Vesicular Stomatitis Virus (VSV). H2-D b restricted epitopes VSV Nucleoprotein (52-59) binds to MHC class I molecules and presents itself to CD8+ T cells, thereby activating cytotoxic T lymphocytes (CTLs), which can recognize and kill cells expressing the corresponding antigen. H2-D b restricted epitopes VSV Nucleoprotein (52-59) can be used in the development of CTL vaccines against Ebola virus .
  • HY-P10610
    Peptide 234CM

    		MDM-2/p53 Cancer
    Peptide 234CM is a peptide containing isoleucine at position 3, corresponding to the sequence of a point mutation in p53 codon 234. Peptide 234CM induces potent cytotoxic T cell (CTL) and antitumor immune responses against mutant p53 .
  • HY-P10496
    MAGE-A1-derived peptide

    		Peptides Cancer
    MAGE-A1-derived peptide is a short peptide sequence derived from MAGE-A1 protein. As a tumor-specific antigen, MAGE-A1-derived peptide can be recognized and activated by cytotoxic T lymphocytes (CTLs), thereby generating an immune response to tumor cells expressing MAGE-A1. This immune response can lead to the lysis and death of tumor cells. MAGE-A1-derived peptide can be used in the study of tumor immunity .
  • HY-P4046
    HBV Seq2 aa:179-186

    		HIV Inflammation/Immunology
    HBV Seq2 aa:179-186 serve as effective motifs for CTL response in H-2b system after in vitro restimulation of the primed T cells. HBV Seq2 aa:179-186 is a novel epitope identified on the surface antigen of hepatitis B virus .
  • HY-P10497
    EBV BZLF1 (190-197)

    		Bacterial Others
    EBV BZLF1 (190-197) is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) is a suitable epitope for CD8+ T cells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) can be used to study autoimmune diseases .
  • HY-P0277
    Carcinoembryonic antigen peptide 1

    CEA peptide

    		 Peptides Cancer
    Carcinoembryonic antigen peptide 1 (CEA peptide) is a carcinoembryonic antigen (CEA)-derived peptide. Carcinoembryonic antigen peptide 1 is a potential HLA-A*0201-restricted CTL epitope that can be used for the study of CTL-mediated epithelial-derived cancers .
  • HY-P10245
    Fusion glycoprotein (92-106)

    		RSV Inflammation/Immunology
    Fusion glycoprotein 92-106 is a polypeptide from fusion protein of respiratory syncytial virus (RSV). Fusion glycoprotein 92-106 acts as MHC class I-restricted CTL epitope, that all 15 amino acids are required for efficient recognition by cytotoxic T lymphocyte (CTL) .
  • HY-P1870
    OVA sequence (323-336)

    		Peptides Inflammation/Immunology
    OVA sequence (323-336) is a cognate helper T-lymphocyte peptide that is employed to enhance CTL epitope immunogenicity.
  • HY-P5501
    Influenza A NP (366-374)

    		Peptides Others
    Influenza A NP (366-374) is a biological active peptide. (H-2Db restricted CTL epitope)
  • HY-P2495
    OVA (241-270)

    		Biochemical Assay Reagents Cancer
    OVA (241-270), a non-specific cytotoxic T lymphocyte (CTL) peptide, is a fragmented peptide of OVA (ovalbumin) antigen .
  • HY-P2495A
    OVA (241-270) TFA

    		Biochemical Assay Reagents Inflammation/Immunology
    OVA (241-270) TFA, a non-specific cytotoxic T lymphocyte (CTL) peptide, is a fragmented peptide of OVA (ovalbumin) antigen .
  • HY-P1881
    HPV16-E711-20 epitope

    		HPV Cancer
    HPV16-E711-20 epitope is a well-known HLA-A *0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .
  • HY-P6355
    CAP1-6D

    		Peptides Inflammation/Immunology
    CAP1-6D is an agonist peptide for cytotoxic T cell (CTL), that enhances the immunogenicity of the CAPI peptide, and stimulates T cell responses .
  • HY-P1757
    HIV p17 Gag (77-85)

    		HIV Infection
    HIV p17 Gag (77-85) is an HLA-A*0201(A2)-restricted CTL epitope, used in the research of anti-HIV .
  • HY-105039
    Disomotide

    G209-2M; GP100:209-217(210M); MPS-22

    		 Peptides Cancer
    Disomotide (G209-2M) is a melanoma antigen that enhances the generation of cytotoxic T lymphocytes (CTL) recognizing native G209 as well as melanoma .
  • HY-P0200
    RR-SRC

    		Src Inflammation/Immunology
    RR-SRC is a substrate for src-tyrosine-specific protein kinase .
  • HY-P10264
    MAGE-3 peptide

    MAGE-3(168-176), human

    		 Peptides Cancer
    MAGE-3 peptide (MAGE-3 168-176, human) is a peptide encoded by human MAGE-3 gene, which is expressed in tumor cells, presented by HLA and recognized by cytolytic T lymphocytes (CTL) as tumor antigen .
  • HY-P5294
    YLLEMLWRL

    		EBV Cancer
    YLLEMLWRL is an HLA-A2-restricted T cell epitope sequence corresponding to codon 125-133. Among them, YLLEMLWRL sequence is the main mutation site of HLA-A2-restricted CTL epitope sequence .
  • HY-P4667
    VLHDDLLEA

    		Peptides Metabolic Disease
    VLHDDLLEA is a peptide that can be isolated from the MHC complex HLA-A*0201 molecule. VLHDDLLEA can be recognized by HLA-A*0201-restricted cytotoxic T cells (CTLs). VLHDDLLEA can be used for research on graft versus host disease (GvHD) .
  • HY-P3742
    Tyrosinase (192-200), human mouse

    		Tyrosinase Cancer
    Tyrosinase (192-200), human mouse is a nonapeptide. Tyrosinase (192-200), human mouse can be recognized by cytolytic T cell (CTL) on the HLA-B44 molecule. Tyrosinase (192-200), human mouse can be used in research of melanoma associated cancers .
  • HY-P5453
    CFP10 (71–85)

    		CD3 Others
    CFP10 (71–85) is a biological active peptide. (CFP1071–85, that elicited IFN-γ production and CTL activity by both CD4+ and CD8+ T cells from persons expressing multiple MHC class II and class I molecules)
  • HY-P5742
    ELAAWCRWGFLLALLPPGIAG

    		EGFR Cancer
    ELAAWCRWGFLLALLPPGIAG (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .
  • HY-P2521
    NS2 (114-121), Influenza

    		Influenza Virus Infection Inflammation/Immunology
    NS2 (114-121), Influenza, the 114-121 fragment of influenza nonstructural protein 2 (NS2), is a influenza-derived epitope. NS2 (114-121), Influenza can be used for the research of CD8 + cytotoxic T lymphocyte (CTL) in antiviral immune responses .
  • HY-106374
    Elpamotide

    		VEGFR Cancer
    Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer .
  • HY-P5742A
    ELAAWCRWGFLLALLPPGIAG TFA

    		EGFR Cancer
    ELAAWCRWGFLLALLPPGIAG TFA (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG TFA can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .
  • HY-P1827
    mTRP-2 (180-188)

    		Tyrosinase Cancer
    mTRP-2 (180-188) is a murine tyrosinase-related protein 2 (TRP-2) -derived peptide, corresponding to residues 180-188. TRP-2 (180-188) is identified as the major reactive epitope within TRP-2 recognized by anti-B16 CTLs .
  • HY-P1862
    HSV-gB2 (498-505)

    		HSV Infection
    HSV-gB2 (498-505) is an immunodominant epitope from herpes simplex virus (HSV) glycoprotein B residues 498-505, acts as H-2Kb-restricted and HSV-1/2-cross-reactive cytotoxic T-lymphocyte (CTL) recognition epitope .
  • HY-P1855
    HER2/neu (654-662) GP2

    		EGFR Cancer
    HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .
  • HY-P10593
    Influenza A NP (383-391) (HLA-B27)

    		Transmembrane Glycoprotein Influenza Virus Cancer
    Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research .
  • HY-P2524
    MAGE-3 (271-279)

    		Peptides Cancer
    MAGE-3 (271-279) is a 271-279 residue peptide derived from melanoma antigens encoded by MAGE-3. MAGE-3 is a cytolytic T lymphocyte (CTL)-defined MAGE-3 protein associated with the human leukocyte antigen (HLA)-A2 molecule. MAGE-3 is overexpressed in different human tumor types, including malignant melanoma, but not by normal tissues except for testis and placenta .
  • HY-P10869
    dCNP

    		Natriuretic Peptide Receptor (NPR) Inflammation/Immunology Cancer
    dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .
  • HY-P10838
    PL120131

    		PD-1/PD-L1 Apoptosis Inflammation/Immunology
    PL120131 is a PD-1/PD-L1 inhibitory peptide that can interfere with the interaction of PD-1/PD-L1 by binding to PD-1. PL120131 is capable of inhibiting the PD-1-mediated apoptotic signaling pathway, protecting Jurkat cells and primary lymphocytes from apoptosis. PL120131 aids in the antitumor activity of cytotoxic T lymphocytes (CTLs) .
  • HY-P1920
    CEF19, Epstein-Barr Virus latent NA-3A (458-466)

    		EBV Inflammation/Immunology
    CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain). CEF19, Epstein-Barr Virus latent NA-3A (458-466) can significantly affect cytotoxic T-lymphocyte (CTL) recognition .
  • HY-P5503
    Pol (476-484), HIV-1 RT Epitope

    		HIV Others
    Pol (476-484), HIV-1 RT Epitope is a biological active peptide. (This is a reverse transcriptase (RT) epitope (Pol residues 476-484). Within HIV-1 RT the peptide appears to be the dominant HLA A*0201-restricted epitope. Was used to investigate possible mechanisms behind HIV-1 escape from CTL. IV9 is the actual epitope processed and presented in HIV-1-infected cell lines.)
  • HY-P10251
    HIV gp120 (318-327)

    		HIV Infection
    HIV gp120 (318-327) is a short sequence of the HIV-1 strain IIIB envelope peptide (rgpgrafvti) that corresponds to the conserved C-terminal region of the glycoprotein. HIV gp120 (318-327) is part of the HIV vaccine V3 peptide epitope, also known as the I10 peptide. However, HIV gp120 (318-327) lacks the A2 anchor residues recognized by epitope-specific CTLs but has structural features that confer promiscuous A2 binding .
  • HY-P10607
    IALYLQQNW

    		EBV Cancer
    IALYLQQNW is a specific nonapeptide sequence derived from the tumor-associated antigen latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus (EBV). As a latent T-cell epitope, IALYLQQNW is able to activate EBV-specific cytotoxic T lymphocytes (CTLs), which are able to recognize and kill EBV-infected cells expressing LMP1. IALYLQQNW plays an important role in the immune response against EBV-associated tumors and can be used in the study of Hodgkin's disease and nasopharyngeal carcinoma .
  • HY-P1571
    Nucleoprotein (396-404)

    NP 396

    		 Arenavirus Inflammation/Immunology
    Nucleoprotein (396-404) is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .
  • HY-P1571A
    Nucleoprotein (396-404) (TFA)

    NP 396 TFA

    		 Arenavirus Inflammation/Immunology
    Nucleoprotein (396-404) TFA is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) TFA is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: